Compare Biogen Inc (BIIB) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Old Dominion Freight Line Inc — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while Old Dominion Freight Line Inc trades at $233 (market cap $47.55B). The key difference: Old Dominion Freight Line Inc is the larger of the two by market cap, and Old Dominion Freight Line Inc pays a 0.51% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | ODFL | |
|---|---|---|
Market Cap | $28.34B | $47.55B |
Sector | Health | Industrials |
52-Week High | $216.63 | $248.73 |
52-Week Low | $122.68 | $126.29 |
Enterprise Value | $30.62B | $47.30B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
ODFL trades at $232.9, up 2.32% today, with a bullish technical signal from moving averages and oscillators. The company maintains strong profitability with an 18.46% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights improving LTL freight demand and a disciplined capital allocation strategy.
Outlook remains positive due to operational strength and market share gains, but elevated valuation multiples and competitive pressures from players like Amazon pose risks. The stock's proximity to its consensus price target of $232.20 suggests limited near-term upside, requiring careful monitoring of Q2 2026 earnings due July 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
